Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

Blog

By Dave Fornell, editor of DAIC Magazine


The key take away messages from the 26th annual Transcatheter Cardiovascular ...

Home September 26, 2014
Home
News
September 26, 2014 — A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus ...
Home September 26, 2014
Home
News

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) ...

Home September 24, 2014
Home
ABSORB II Study DES Xience Abbot Vascular
Feature

September 24, 2014 — Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective ...

Home September 24, 2014
Home
Videos | Stents Bioresorbable

DAIC Editor, Dave Fornell, interviews  Jim Hermiller, M.D., FACC, director of interventional cardiology, St. Vincent ...

Home September 24, 2014
Home
bioresorbable stents, dissolving stents, Absorb stent, BVS
Feature | Stents Bioresorbable | Dave Fornell
Home September 03, 2014
Home
News

July 10, 2014 — 480 Biomedical announced it has been awarded Phase II funding from the National Heart, Lung, and Blood ...

Home July 10, 2014
Home
Elixir Medical Corp. DESolve 100 CE mark
Feature

May 13, 2014 — Elixir Medical Corp. received European CE mark approval for its DESolve 100 Novolimus-eluting Bioresorbab ...

Home May 13, 2014
Home
Feature

April 16, 2014 — Abbott announced it has completed enrollment of three clinical trials to support approvals of the ...

Home April 16, 2014
Home
Videos | Stents Bioresorbable

Bioresorbable stent technology was one of the big interventional technologies discussed at the American College of ...

Home April 03, 2014
Home
Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent
Feature

March 31, 2014 — Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo ...

Home March 31, 2014
Home
News

March 12, 2014 — Micell Technologies Inc. announced that imaging and clinical results from the DESSOLVE I and DESSOLVE ...

Home March 12, 2014
Home
News

January 23, 2014 – Six-month results of the ESPRIT trial suggest a bioresorbable drug-eluting scaffold is effective in ...

Home January 23, 2014
Home
News
January 23, 2014 — An implant of the ReZolve2 bioresorbable scaffold was transmitted live via satellite at the ...
Home January 23, 2014
Home
News
January 22, 2014 — The first commercial implant of Elixir Medical’s CE Mark-approved DESolve Novolimus Eluting Coronary ...
Home January 22, 2014
Home
Subscribe Now